1-8 of 8
Deborah K. Armstrong
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

Stephanie L. Wethington, Payal D. Shah, Lainie Martin, Janos L. Tanyi, Nawar Latif, Mark Morgan, Drew A. Torigian, Diego Rodriguez, Simon A. Smith, Emma Dean, Susan M. Domchek, Ronny Drapkin, Ie-Ming Shih, Eric J. Brown, Wei-Ting Hwang, Deborah K. Armstrong, Stephanie Gaillard, Robert Giuntoli, Fiona Simpkins
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (15): 2800–2807.
https://doi.org/10.1158/1078-0432.CCR-22-2444
Published: 01 August 2023
View article titled, C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
Open the PDF for C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A72: Combination ATR and PARP inhibitor (CAPRI) for recurrent, platinum-resistant ovarian cancer

Payal D. Shah, Haley Zarrin, Stephanie Wethington, Nawar Latif, Lainie Martin, Diego Rodriguez, Katie Elkins, Robert Giuntoli, Robert Burger, Janos Tanyi, Mark Morgan, Susan M. Domchek, Stephanie Gailliard, Deborah K. Armstrong, Fiona Simpkins
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): A72.
https://doi.org/10.1158/1557-3265.OVCA19-A72
Published: 01 July 2020
View article titled, Abstract A72: Combination ATR and PARP inhibitor (CAPRI) for recurrent, platinum-resistant ovarian cancer
Journal Articles

The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial

Cesar A. Santa-Maria, Janelle W. Coughlin, Dipali Sharma, Mary Armanios, Amanda L. Blackford, Colleen Schreyer, Arlene Dalcin, Ashley Carpenter, Gerald J. Jerome, Deborah K. Armstrong, Madhu Chaudhry, Gary I. Cohen, Roisin M. Connolly, John Fetting, Robert S. Miller, Karen L. Smith, Claire Snyder, Andrew Wolfe, Antonio C. Wolff, Chiung-Yu Huang, Lawrence J. Appel, Vered Stearns
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12): 3024–3034.
https://doi.org/10.1158/1078-0432.CCR-19-2935
Published: 15 June 2020
View article titled, The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial
Open the PDF for The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Amit M. Oza, Ursula A. Matulonis, Angeles Alvarez Secord, John Nemunaitis, Lynda D. Roman, Sarah P. Blagden, Susana Banerjee, William P. McGuire, Sharad Ghamande, Michael J. Birrer, Gini F. Fleming, Merry Jennifer Markham, Hal W. Hirte, Diane M. Provencher, Bristi Basu, Rebecca Kristeleit, Deborah K. Armstrong, Benjamin Schwartz, Patricia Braly, Geoff D. Hall, Kenneth P. Nephew, Simone Jueliger, Aram Oganesian, Sue Naim, Yong Hao, Harold Keer, Mohammad Azab, Daniela Matei
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (5): 1009–1016.
https://doi.org/10.1158/1078-0432.CCR-19-1638
Published: 02 March 2020
View article titled, A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Open the PDF for A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Advancing Drug Development in Gynecologic Malignancies

Julia A. Beaver, Robert L. Coleman, Rebecca C. Arend, Deborah K. Armstrong, Sanjeeve Bala, Gordon B. Mills, Anil K. Sood, Thomas J. Herzog
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (16): 4874–4880.
https://doi.org/10.1158/1078-0432.CCR-19-0619
Published: 15 August 2019
View article titled, Advancing Drug Development in Gynecologic Malignancies
Open the PDF for Advancing Drug Development in Gynecologic Malignancies in another window
Journal Articles

Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors

David M. Hyman, Naiyer Rizvi, Ronald Natale, Deborah K. Armstrong, Michael Birrer, Lawrence Recht, Efrat Dotan, Vicky Makker, Thomas Kaley, Denison Kuruvilla, Matthew Gribbin, Jennifer McDevitt, Dominic W. Lai, Mohammed Dar
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (12): 2749–2757.
https://doi.org/10.1158/1078-0432.CCR-17-1775
Published: 14 June 2018
View article titled, Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors
Open the PDF for Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.

Wells A Messersmith, Sharyn D Baker, Lance Lassiter, Rana A Sullivan, Kimberly Dinh, Virna I Almuete, John J Wright, Ross C Donehower, Michael A Carducci, Deborah K Armstrong
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (4): 1270–1275.
https://doi.org/10.1158/1078-0432.CCR-05-1942
Published: 17 February 2006
View article titled, Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
Open the PDF for Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. in another window
Journal Articles

A Phase II Study of the Polyamine Analog N 1, N 11-Diethylnorspermine (DENSpm) Daily for Five Days Every 21 Days in Patients with Previously Treated Metastatic Breast Cancer

Antonio C. Wolff, Deborah K. Armstrong, John H. Fetting, M. Katherine Carducci, Carol D. Riley, John F. Bender, Robert A. Casero, Jr., Nancy E. Davidson
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (16): 5922–5928.
Published: 15 December 2003
View article titled, A Phase II Study of the Polyamine Analog <em>N</em> <sup>1</sup>, <em>N</em> <sup>11</sup>-Diethylnorspermine (DENSpm) Daily for Five Days Every 21 Days in Patients with Previously Treated Metastatic Breast Cancer
Open the PDF for A Phase II Study of the Polyamine Analog <em>N</em> <sup>1</sup>, <em>N</em> <sup>11</sup>-Diethylnorspermine (DENSpm) Daily for Five Days Every 21 Days in Patients with Previously Treated Metastatic Breast Cancer in another window